11.17
-0.03(-0.27%)
Currency In USD
Address
12730 High Bluff Drive
San Diego, CA 92130
United States of America
Phone
858 500 8800
Website
Sector
Healthcare
Industry
Biotechnology
Employees
142
First IPO Date
September 16, 2015
| Name | Title | Pay | Year Born |
| Dr. Troy Edward Wilson J.D., Ph.D. | Chairman, Chief Executive Officer & President | 1.22M | 1969 |
| Ms. Teresa Brophy Bair Esq., J.D. | Chief Legal Officer & Corporate Secretary | 705,385 | 1971 |
| Ms. Kathleen Ford | Chief Operating Officer | 824,946 | 1947 |
| Dr. Stephen Dale M.D. | Chief Medical Officer | 855,297 | 1972 |
| Mr. Thomas Doyle | Senior Vice President of Finance & Accounting | 0 | 1971 |
| Ms. Maureen Clancy M.B.A. | Vice President and Global Head of Program Leadership & Project Management | 0 | N/A |
| Dr. Roger Bakale Ph.D. | Senior Vice President of Manufacturing & Supply Chain | 0 | N/A |
| Mr. Brian T. Powl M.B.A., M.S. | Chief Commercial Officer | 0 | 1974 |
| Mr. Pete De Spain | Executive Vice President of Investor Relations & Corporate Communications | 0 | N/A |
| Dr. Mollie Leoni M.D. | Executive Vice President of Clinical Development | 0 | N/A |
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.